LRRC15 and breast carcinoma: discovered that LRRC15+ myCAFs in pancreatic cancer are activated by TGF‐β.[62] Yann Kieffer found that LAMP5+ myCAF in breast cancer is mainly activated by TGF‐β,[63] whereas the TME subtype that specifically accepts TGF‐β in CRC has not been fully clarified, which limits antitumor therapy via TGF‐β targeting.